Cortexyme (CRTX) Appoints Marwan Sabbagh to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/2/2026
- Wall St set to open higher after June jobs report eases rate hike bets
- Oil falls for a third straight day after US, Iran conclude talks in Doha
- Bond prices and stocks rally on softer payrolls, dollar falls
- Meta Platforms stock surges 8% on cloud business plans
- Humanoid robot component stocks surge on supply-chain optimism
Cortexyme Appoints Marwan Sabbagh, MD, to its Board of Directors
March 15, 2022 8:00 AM EDTSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the appointment of Marwan Noel Sabbagh, MD, FAAN, a board-certified neurologist and leading expert in Alzheimers and dementia care, to the companys Board of Directors.
Dr. Sabbaghs deep expertise in neurological diseases and extensive clinical development experience makes him a valuable addition to the Cortexyme Board of Directors, said Chris Lowe, Cortexymes interim chief executive officer. Cortexyme will benefit... More
